MedTrace Logo

Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies

NCT06412718 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 274

Last updated 2024-05-14

No results posted yet for this study

Summary

The cross-sectional observational clinical study related to rare eye diseases is a multi-center study in which the hypothesis is that neurokinin 1 receptor and/or substance P expression is increased in REDs associated with inflammation/pain. Moreover, the following alternative targets are: VEGF, PAX6 and pro-inflammatory cytokine.

The following procedures are performed specifically for the study: samples of blood, tear fluid and impression cytology.

Precisely during the ophthalmological exam performed according to normal clinical practice (uncorrected visual acuity, best spectacle corrected visual acuity, corneal topography, corneal pachymetry and the slit lamp pictures) investigator's team collect the samples of blood, tear fluid and impression cytology to evaluate the goal of the study.

Conditions

  • Rare Diseases
  • Aniridia
  • Neurotrophic Keratopathy
  • Limbal Stem Cell Deficiency
  • Ocular Graft-versus-host Disease
  • Ocular Cicatricial Pemphigoid
  • EEC Syndrome
  • Corneal Neovascularization

Sponsors & Collaborators

  • IRCCS Ospedale San Raffaele

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2025-04-30
Completion
2026-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06412718 on ClinicalTrials.gov